+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Low-dose hepatitis B immunoglobulin given on demand in combination with lamivudine: A highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation



Low-dose hepatitis B immunoglobulin given on demand in combination with lamivudine: A highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation



Transplantation 77(8): 1203-1208, April 27



Background. Cost of long-term prophylaxis with high-dose human hepatitis B immune globulin (HBIg) after liver transplantation is extremely high. The aim of the present study was to assess consumption rate of high (5,000 IU) and low (2,000 IU) doses of HBIg given intravenously "on demand," and determine their cost-effectiveness compared with conventional fixed monthly schedules. Methods. The study included 11 male patients (mean age 53 years) who received transplants for hepatitis I virus (HBV)-related cirrhosis 29 to 96 months earlier all receiving lamivudine (100 mg/day) prophylaxis Each patient received three consecutive intravenous infusions of 5,000 IU HBIg, followed by three 2,000 IU infusions. HBIg consumption was assessed by serial measurement of serum hepatitis B surface antibody (HBsAb) titer at 2-week intervals. HBIg was readmin- istered only when HBsAb titers dropped below 70 IU/L (i.e., "on demand"). Results. Mean HBsAb peak titers after high and low HBIg doses were 1,641+/-385 and 848+/-216 IU/L, respec- tively (P<0.0001). Mean time to reach an HBsAb titer less than 70 IU/L was 79.5+/-38.2 days versus 61.6+/-32.1. days, respectively (P=NS). Interindividual variation coefficients were 23+/-18% and 32+/-26% (5,000 IU and 2,000 IU, respectively). Using the on demand ap- proach, maintenance of a protective anti-HBs titer re quired an average number of 4.0 (5,000 IU) and 5.6 (2,000 IU) HBIg administrations per year, respectively (P=NS). Conclusions. Individual HBIg consumption profile are highly variable. A low-dose (2,000 IU) on demand HBIg administration schedule is highly cost-effective and provides more than 50% savings compared with conventional high-dose monthly schedules.

(PDF emailed within 0-6 h: $19.90)

Accession: 012276840

Download citation: RISBibTeXText

PMID: 15114086

DOI: 10.1097/01.tp.0000118904.63669.eb


Related references

Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transplantation 9(2): 182-187, 2003

Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 83(2): 231-233, 2007

Lamivudine Plus Low-Dose Hepatitis B Immunoglobulin to Prevent Recurrent Hepatitis B Following Liver Transplantation. Yearbook of Gastroenterology 2007: 277-278, 2007

Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132(3): 931-937, 2007

Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antiviral Therapy 9(6): 921-927, 2005

Long-term combination HBIG and lamivudine is highly effective in preventing recurrent hepatitis B in orthotopic liver transplant recipients. Hepatology 28(4 PART 2): 222A, 1998

Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation. Transplantation 97 Suppl 8(): S53-S59, 2014

Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation. Clinical Transplantation 25(4): 517-522, 2012

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transplantation 6(6): 741-748, 2000

Low vs high dose hepatitis B immunoglobulins on demand and lamivudine in liver transplant recipients A new cost-effective strategy to prevent HBV reinfection. Gastroenterology 122(4 Suppl 1): A 632, 2002

Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clinical Transplantation 17(3): 254-258, 2003

Combination lamivudine plus low dose intramuscular hepatitis B immunoglobulin prevents recurrent hepatitis B and may eradicate residual graft infection. Hepatology 36(4 Part 2): 221A, 2002

Recurrent hepatitis C virus infection after liver transplantation--long-term follow-up with respect to the HCV genotypes/subtypes. Zeitschrift für Gastroenterologie 35(4): 255-261, 1997

Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. American Journal of Transplantation 3(8): 999-1002, 2003

Limited lamivudine and long-term hepatitis B immunoglobulin immunoprophylaxis for prevention of hepatitis B recurrence after liver transplantation. Transplantation 74(3): 408-410, 2002